Evidence map›Paper›PMID 41094656›Full record

ReviewMolecular cancer2025

Targeting metalloptosis in tumor therapy: from molecular mechanisms to application of metal nanoparticles.

Jinxiang Wang, Qin Tian, Yuchen Liu, Chao-Yun Cai, Shuying Fu, Jia Li, Yupeng Guan, Xuankai Liao, Danting Su, Tuanwei Sun and 6 more

Abstract readReview
In one paragraph

Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. [Role of programmed cell death in platinum resistance in ovarian cancer].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jinxiang Wang *Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.
Qin Tian *Department of Orthopedic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.
Yuchen Liu *Scientific Research Center,the biobank, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.
Chao-Yun CaiScientific Research Center,the biobank, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.
Shuying FuDepartment of Dermatology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.
Jia LiScientific Research Center,the biobank, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.
Yupeng GuanDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.
Xuankai LiaoDepartment of Pathology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen Guangdong, 518107, China.
Danting SuDepartment of Pathology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen Guangdong, 518107, China.
Tuanwei SunDepartment of Orthopedic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China.
Yong ZhangDepartment of Biomedical Engineering, City University of Hong Kong, Hong Kong, China.
Rubing LinDepartment of Orthopedics, Shenzhen Children's Hospital, Shenzhen, 518000, Guangdong, China.
Yuzhi XuScientific Research Center,the biobank, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. xuyzh28@mail.sysu.edu.cn.
Jun PangDepartment of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. pangjun2@mail.sysu.edu.cn.
Leli ZengScientific Research Center,the biobank, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. zenglli6@mail.sysu.edu.cn.
Yihang PanScientific Research Center,the biobank, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. panyih@mail.sysu.edu.cn.

Funding

Guangdong Province key field research and development plan Grant No. 2023B1111040002the Guangdong Basic and Applied Basic Research Foundation Grant No. 2023A1515010156the Guangdong Basic and Applied Basic Research Foundation Grant No. 2023A1515111044the Guangdong Basic and Applied Basic Research Foundation Grant No.2025B1515020001the National Key Research and Development Program 2023YFF1501203The National Natural Science Foundation of China 22477150The National Natural Science Foundation of China 32270815the Research Start-up Fund of Post-doctoral of SAHSYSU Grant No. ZSQYRSFPD0067the Shenzhen Science and Technology Program Grant No. GJHZ20220913142400001the Shenzhen Science and Technology Program Grant No. RCBS20231211090733052the Shenzhen Science and Technology Program Grant No. SGDX20240115111759001
6 · The paper itself

Abstract

Metal ions-based regulated cell death (RCD), a form of cell death involving metal ions and controlled by one or more cascade signaling pathways, has recently been termed "metalloptosis". Given the rapid advances in understanding metalloptosis in malignant progression and nanotherapeutics, this review elucidates the latest progress in metalloptosis, focusing on the roles of various metal ions and the targeting of metalloptosis in cancer therapy and nanomedicine. We briefly describe the essential discoveries of RCD and comprehensively summarize the current major regulatory signaling pathways of emerging metalloptosis forms, including ferroptosis, cuproptosis, lysozincrosis, manganism, calcicoptosis, and necrosis by sodium overload (NECSO). Additionally, we demonstrated the effects of metalloptosis on malignant neoplastic progression and the tumor microenvironment (TME). Furthermore, we discuss the feasibility of targeting metalloptosis pathways using metal nanoparticles (MNPs) for cancer therapy and overcoming drug resistance in cancer cells. We hope that this review will provide both fundamental insights and translational outlooks for harnessing metalloptosis in precision oncology.

Indexed as

Antineoplastic AgentsMetal NanoparticlesMetalsNeoplasmsAnimalsHumansNanomedicineSignal TransductionTumor MicroenvironmentAntineoplastic AgentsMetalsCancer therapyDrug resistanceMetalloptosisMetal nanoparticles (MNPs)NanomedicineRegulated cell death

Identifiers

PMID41094656
PMCPMC12529859

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.